Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MCRPC (metastatic Castration-resistant Prostate Cancer)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04495179
What this trial is testing

AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

Who this might be right for
Progressive Metastatic Castrate-Resistant Prostate Cancer
AstraZeneca 30
Testing effectiveness (Phase 2)Study completedNCT04862091
What this trial is testing

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Jiangsu HengRui Medicine Co., Ltd. 69
Testing effectiveness (Phase 2)WithdrawnNCT03173859
What this trial is testing

Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
University of Athens
Testing effectiveness (Phase 2)Looking for participantsNCT06241846
What this trial is testing

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
MediLink Therapeutics (Suzhou) Co., Ltd. 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT05383079
What this trial is testing

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate CancerMCRPCProstate Cancer
Peter MacCallum Cancer Centre, Australia 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07592910
What this trial is testing

Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Prostate Cancer (Adenocarcinoma)
Prostate Cancer Clinical Trials Consortium 60
Testing effectiveness (Phase 2)Ended earlyNCT04918810
What this trial is testing

Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Castration Resistant Prostatic Cancer
Australian and New Zealand Urogenital and Prostate Cancer Trials Group 6
Large-scale testing (Phase 3)Not Yet RecruitingNCT06768255
What this trial is testing

Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC

Who this might be right for
Abiraterone AcetateMCRPC (metastatic Castration-resistant Prostate Cancer)
Ding-Wei Ye 400
Testing effectiveness (Phase 2)Study completedNCT02494921
What this trial is testing

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

Who this might be right for
Prostate Cancer
Rahul Aggarwal 43
Large-scale testing (Phase 3)Active Not RecruitingNCT04689828
What this trial is testing

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Novartis Pharmaceuticals 469
Testing effectiveness (Phase 2)Looking for participantsNCT06842498
What this trial is testing

FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Kyntra Bio 75
Large-scale testing (Phase 3)Active Not RecruitingNCT04691804
What this trial is testing

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Jiangsu HengRui Medicine Co., Ltd. 496
Early research (Phase 1)Ended earlyNCT04615845
What this trial is testing

Autologous Dendritic Cell Immunotherapy in Patients With mCRPC

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Pharmicell Co., Ltd. 3
Early research (Phase 1)Study completedNCT05544227
What this trial is testing

Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Williams Cancer Foundation 15
Testing effectiveness (Phase 2)UnknownNCT03085966
What this trial is testing

Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Shanghai AbelZeta Ltd. 30
Large-scale testing (Phase 3)Looking for participantsNCT07611110
What this trial is testing

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
AstraZeneca 670
Early research (Phase 1)Active Not RecruitingNCT07214961
What this trial is testing

Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer (CRPC)Metastatic Castrate Resistant Prostate Cancer (mCRPC)
ARTBIO Inc. 80
Testing effectiveness (Phase 2)Looking for participantsNCT07226986
What this trial is testing

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Who this might be right for
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals 123
Not applicableEnded earlyNCT03011749
What this trial is testing

Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients

Who this might be right for
Metastatic Prostate Carcinoma
Rigshospitalet, Denmark 6
Not applicableWithdrawnNCT02130947
What this trial is testing

Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
UNC Lineberger Comprehensive Cancer Center
Next Page